Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 9/2010

Open Access 01-09-2010 | Review

Anti-HER2 vaccines: new prospects for breast cancer therapy

Authors: Maha Zohra Ladjemi, William Jacot, Thierry Chardès, André Pèlegrin, Isabelle Navarro-Teulon

Published in: Cancer Immunology, Immunotherapy | Issue 9/2010

Login to get access

Abstract

Each year, breast cancer accounts for more than 400,000 new cancer cases and more than 130,000 cancer deaths in Europe. Prognosis of nonmetastatic breast cancer patients is directly related to the extent of the disease, mainly nodal spreading and tumor size, and to the molecular profile, particularly HER2 over-expression. In patients with HER2-over-expressing tumors, different studies have shown cellular and/or humoral immune responses against HER2 associated with a lower tumor development at early stages of the disease. These findings have led to the hypothesis that the generation of an anti-HER2 immune response should protect patients from HER2-over-expressing tumor growth. Taken together with the clinical efficiency of trastuzumab-based anti-HER2 passive immunotherapy, these observations allowed to envisage various vaccine strategies against HER2. The induction of a stable and strong immunity by cancer vaccines is expected to lead to establishment of immune memory, thereby preventing tumor recurrence. However, an immunological tolerance against HER2 antigen exists representing a barrier to effective vaccination against this oncoprotein. As a consequence, the current challenge for vaccines is to find the best conditions to break this immunological tolerance. In this review, we will discuss the different anti-HER2 vaccine strategies currently developed; considering the strategies having reached the clinical phases as well as those still in preclinical development. The used antigen can be either composed of tumoral allogenic cells or autologous cells, or specific to HER2. It can be delivered by dendritic cells or in a DNA, peptidic or proteic form. Another area of research concerns the use of anti-idiotypic antibodies mimicking HER2.
Literature
1.
Slichenmyer WJ, Fry DW (2001) Anticancer therapy targeting the erbB family of receptor tyrosine kinases. Semin Oncol 28:67–79PubMedCrossRef
2.
Schmidt M, Lewark B, Kohlschmidt N et al (2005) Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Res 7:R256–266PubMedCrossRef
3.
Martín M, Rodríguez-Lescure A, Ruiz A et al (2008) Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst 100:805–814PubMedCrossRef
4.
Ross JS, Fletcher JA (1998) The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy. Oncologist 3:237–252PubMed
5.
Peoples GE, Goedegebuure PS, Smith R, Linehan DC, Yoshino I, Eberlein TJ (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92:432–436PubMedCrossRef
6.
Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792PubMedCrossRef
7.
Nahta R, Esteva FJ (2006) Herceptin: mechanisms of action and resistance. Cancer Lett 232:123–138PubMedCrossRef
8.
Berns K, Horlings HM, Hennessy BT et al (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12:395–402PubMedCrossRef
9.
Cobleigh MA, Vogel CL, Tripathy D et al (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17:2639–2648PubMed
10.
Bengala C, Zamagni C, Pedrazzoli P et al (2006) Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study. Br J Cancer 94:1016–1020PubMedCrossRef
11.
Disis ML, Calenoff E, McLaughlin G et al (1994) Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54:16–20PubMed
12.
Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181:2109–2117PubMedCrossRef
13.
Disis ML, Bernhard H, Shiota FM et al (1996) Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines. Blood 88:202–210PubMed
14.
Huber CH, Wölfel T (2004) Immunotherapy of cancer: from vision to standard clinical practice. J Cancer Res Clin Oncol 130:367–374PubMedCrossRef
15.
16.
Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A (1990) Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 50:1550–1558PubMed
17.
Pegram MD, Pauletti G, Slamon DJ (1998) HER-2/neu as a predictive marker of response to breast cancer therapy. Breast Cancer Res Treat 52:65–77PubMedCrossRef
18.
Winer EP, Burstein HJ (2001) New combinations with herceptin in metastatic breast cancer. Oncology 61(Suppl 2):50–57PubMedCrossRef
19.
Rilke F, Colnaghi MI, Cascinelli N et al (1991) Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49:44–49PubMedCrossRef
20.
Disis ML, Shiota FM, Cheever MA (1998) Human HER-2/neu protein immunization circumvents tolerance to rat neu: a vaccine strategy for ‘self’ tumour antigens. Immunology 93:192–199PubMedCrossRef
21.
22.
Dakappagari NK, Douglas DB, Triozzi PL, Stevens VC, Kaumaya PT (2000) Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine. Cancer Res 60:3782–3789PubMed
23.
Disis ML, Gralow JR, Bernhard H, Hand SL, Rubin WD, Cheever MA (1996) Peptide-based, but not whole protein, vaccines elicit immunity to HER-2/neu, oncogenic self-protein. J Immunol 156:3151–3158PubMed
24.
Disis ML, Gooley TA, Rinn K et al (2002) Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines. J Clin Oncol 20:2624–2632PubMedCrossRef
25.
Concetti A, Amici A, Petrelli C, Tibaldi A, Provinciali M, Venanzi FM (1996) Autoantibody to p185erbB2/neu oncoprotein by vaccination with xenogenic DNA. Cancer Immunol Immunother 43:307–315PubMedCrossRef
26.
Di Carlo E, Rovero S, Boggio K et al (2001) Inhibition of mammary carcinogenesis by systemic interleukin 12 or p185neu DNA vaccination in Her-2/neu transgenic BALB/c mice. Clin Cancer Res 7:830s–837sPubMed
27.
Pilon SA, Piechocki MP, Wei WZ (2001) Vaccination with cytoplasmic ErbB-2 DNA protects mice from mammary tumor growth without anti-ErbB-2 antibody. J Immunol 167:3201–3206PubMed
28.
Curigliano G, Spitaleri G, Pietri E et al (2006) Breast cancer vaccines: a clinical reality or fairy tale? Ann Oncol 17:750–762PubMedCrossRef
29.
Lollini P, De Giovanni C, Pannellini T, Cavallo F, Forni G, Nanni P (2005) Cancer immunoprevention. Future Oncol 1:57–66PubMedCrossRef
30.
Seavey MM, Pan Z, Maciag PC et al (2009) A novel human Her-2/neu chimeric molecule expressed by Listeria monocytogenes can elicit potent HLA-A2 restricted CD8-positive T cell responses and impact the growth and spread of Her-2/neu-positive breast tumors. Clin Cancer Res 15:924–932PubMedCrossRef
31.
Holmes JP, Benavides LC, Gates JD et al (2008) Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 26:3426–3433PubMedCrossRef
32.
33.
Dols A, Smith JW, Meijer SL et al (2003) Vaccination of women with metastatic breast cancer, using a costimulatory gene (CD80)-modified, HLA-A2-matched, allogeneic, breast cancer cell line: clinical and immunological results. Hum Gene Ther 14:1117–1123PubMedCrossRef
34.
Dols A, Meijer SL, Hu H et al (2003) Identification of tumor-specific antibodies in patients with breast cancer vaccinated with gene-modified allogeneic tumor cells. J Immunother 26:163–170PubMedCrossRef
35.
Kim PS, Armstrong TD, Song H et al (2008) Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs. J Clin Invest 118:1700–1711PubMedCrossRef
36.
Park JW, Melisko ME, Esserman LJ, Jones LA, Wollan JB, Sims R (2007) Treatment with autologous antigen-presenting cells activated with the HER-2 based antigen Lapuleucel-T: results of a phase I study in immunologic and clinical activity in HER-2 overexpressing breast cancer. J Clin Oncol 25:3680–3687PubMedCrossRef
37.
Sakai Y, Morrison BJ, Burke JD et al (2004) Vaccination by genetically modified dendritic cells expressing a truncated neu oncogene prevents development of breast cancer in transgenic mice. Cancer Res 64:8022–8028PubMedCrossRef
38.
Chen Y, Emtage P, Zhu Q et al (2001) Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12. Gene Ther 8:316–323PubMedCrossRef
39.
Chen Z, Huang H, Chang T et al (2002) Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor. Cancer Gene Ther 9:778–786PubMedCrossRef
40.
Campbell M, Qu S, Wells S, Sugandha H, Jensen RA (2003) An adenoviral vector containing an arg–gly–asp (RGD) motif in the fiber knob enhances protein product levels from transgenes refractory to expression. Cancer Gene Ther 10:559–570PubMedCrossRef
41.
Sas S, Chan T, Sami A, El-Gayed A, Xiang J (2008) Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice. Cancer Gene Ther 15:655–666PubMedCrossRef
42.
Chan T, Sami A, El-Gayed A, Guo X, Xiang J (2006) HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination. Gene Ther 13:1391–1402PubMedCrossRef
43.
Viehl CT, Becker-Hapak M, Lewis JS et al (2005) A tat fusion protein-based tumor vaccine for breast cancer. Ann Surg Oncol 12:517–525PubMedCrossRef
44.
Brossart P, Wirths S, Stuhler G, Reichardt VL, Kanz L, Brugger W (2000) Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells. Blood 96:3102–3108PubMed
45.
Czerniecki BJ, Koski GK, Koldovsky U et al (2007) Targeting HER-2/neu in early breast cancer development using dendritic cells with staged interleukin-12 burst secretion. Cancer Res 67:1842–1852PubMedCrossRef
46.
Wei WZ, Shi WP, Galy A et al (1999) Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA. Int J Cancer 81:748–754PubMedCrossRef
47.
Piechocki MP, Pilon SA, Wei WZ (2001) Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human ErbB-2. J Immunol 167:3367–3374PubMed
48.
Wei W, Jacob JB, Zielinski JF et al (2005) Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25+ regulatory T cell-depleted mice. Cancer Res 65:8471–8478PubMedCrossRef
49.
Jacob J, Radkevich O, Forni G et al (2006) Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice. Cell Immunol 240:96–106PubMedCrossRef
50.
Jacob JB, Kong YM, Meroueh C et al (2007) Control of Her-2 tumor immunity and thyroid autoimmunity by MHC and regulatory T cells. Cancer Res 67:7020–7027PubMedCrossRef
51.
Rovero S, Amici A, Di Carlo E et al (2000) DNA vaccination against rat her-2/Neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice. J Immunol 165:5133–5142PubMed
52.
Gallo P, Dharmapuri S, Nuzzo M et al (2005) Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector. Int J Cancer 113:67–77PubMedCrossRef
53.
Aurisicchio L, Peruzzi D, Conforti A et al (2009) Treatment of mammary carcinomas in HER-2 transgenic mice through combination of genetic vaccine and an agonist of Toll-like receptor 9. Clin Cancer Res 15:1575–1584PubMedCrossRef
54.
Radkevich-Brown O, Jacob J, Kershaw M, Wei W (2009) Genetic regulation of the response to Her-2 DNA vaccination in human Her-2 transgenic mice. Cancer Res 69:212–218PubMedCrossRef
55.
Jacob JB, Kong YM, Nalbantoglu I, Snower DP, Wei W (2009) Tumor regression following DNA vaccination and regulatory T cell depletion in neu transgenic mice leads to an increased risk for autoimmunity. J Immunol 182:5873–5881PubMedCrossRef
56.
Disis ML, Schiffman K, Guthrie K et al (2004) Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine. J Clin Oncol 22:1916–1925PubMedCrossRef
57.
Disis ML, Goodell V, Schiffman K, Knutson KL (2004) Humoral epitope-spreading following immunization with a HER-2/neu peptide based vaccine in cancer patients. J Clin Immunol 24:571–578PubMedCrossRef
58.
Knutson KL, Schiffman K, Disis ML (2001) Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients. J Clin Invest 107:477–484PubMedCrossRef
59.
Butterfield LH, Ribas A, Dissette VB et al (2003) Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res 9:998–1008PubMed
60.
Disis ML, Strickler J, Wallace D et al. (2008) Cellular immune parameters associated with improved long-term survival in advanced stage breast cancer patients after active immunization with a HER2-specific vaccine. ASCO Abstract 3015
61.
Webster D, Waisman J, Macleod B et al. (2006) A phase I/II study of a HER2/neu (HER2) peptide vaccine plus concurrent trastuzumab. ASCO Abstract 2528
62.
Mittendorf EA, Holmes JP, Ponniah S, Peoples GE (2008) The E75 HER2/neu peptide vaccine. Cancer Immunol Immunother 57:1511–1521PubMedCrossRef
63.
Lustgarten J, Theobald M, Labadie C et al (1997) Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD8. Hum Immunol 52:109–118PubMedCrossRef
64.
Anderson BW, Peoples GE, Murray JL, Gillogly MA, Gershenson DM, Ioannides CG (2000) Peptide priming of cytolytic activity to HER-2 epitope 369–377 in healthy individuals. Clin Cancer Res 6:4192–4200PubMed
65.
Knutson KL, Schiffman K, Cheever MA, Disis ML (2002) Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369–377, results in short-lived peptide-specific immunity. Clin Cancer Res 8:1014–1018PubMed
66.
Murray JL, Gillogly ME, Przepiorka D et al (2002) Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369–377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. Clin Cancer Res 8:3407–3418PubMed
67.
Zaks TZ, Rosenberg SA (1998) Immunization with a peptide epitope (p369–377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors. Cancer Res 58:4902–4908PubMed
68.
Peoples GE, Gurney JM, Hueman MT et al (2005) Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 23:7536–7545PubMedCrossRef
69.
Peoples GE, Holmes JP, Hueman MT et al (2008) Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 14:797–803PubMedCrossRef
70.
Hueman MT, Stojadinovic A, Storrer CE et al (2006) Levels of circulating regulatory CD4+ CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine. Breast Cancer Res Treat 98:17–29PubMedCrossRef
71.
Shimizu J, Yamazaki S, Sakaguchi S (1999) Induction of tumor immunity by removing CD25+ CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 163:5211–5218PubMed
72.
Benavides LC, Gates JD, Carmichael MG et al (2009) The impact of HER2/neu expression level on response to the E75 vaccine: from U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res 15:2895–2904PubMedCrossRef
73.
Mittendorf EA, Storrer CE, Shriver CD, Ponniah S, Peoples GE (2006) Investigating the combination of trastuzumab and HER2/neu peptide vaccines for the treatment of breast cancer. Ann Surg Oncol 13:1085–1098PubMedCrossRef
74.
Mittendorf EA, Storrer CE, Foley RJ et al (2006) Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 106:2309–2317PubMedCrossRef
75.
Lekka E, Gritzapis AD, Perez SA et al (2010) Identification and characterization of a HER-2/neu epitope as a potential target for cancer immunotherapy. Cancer Immunol Immunother 59:715–727PubMedCrossRef
76.
Yip YL, Smith G, Koch J, Dübel S, Ward RL (2001) Identification of epitope regions recognized by tumor inhibitory and stimulatory anti-ErbB-2 monoclonal antibodies: implications for vaccine design. J Immunol 166:5271–5278PubMed
77.
Dakappagari NK, Pyles J, Parihar R, Carson WE, Young DC, Kaumaya PTP (2003) A chimeric multi-human epidermal growth factor receptor-2 B cell epitope peptide vaccine mediates superior antitumor responses. J Immunol 170:4242–4253PubMed
78.
Cho H, Mason K, Ramyar KX et al (2003) Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756–760PubMedCrossRef
79.
Garrett JT, Rawale S, Allen SD et al (2007) Novel engineered trastuzumab conformational epitopes demonstrate in vitro and in vivo antitumor properties against HER-2/neu. J Immunol 178:7120–7131PubMed
80.
Riemer AB, Klinger M, Wagner S et al (2004) Generation of Peptide mimics of the epitope recognized by trastuzumab on the oncogenic protein Her-2/neu. J Immunol 173:394–401PubMed
81.
Jasinska J, Wagner S, Radauer C et al (2003) Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu. Int J Cancer 107:976–983PubMedCrossRef
82.
Wagner S, Jasinska J, Breiteneder H et al (2007) Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice. Breast Cancer Res Treat 106:29–38PubMedCrossRef
83.
Azuma K, Shichijo S, Shomura H, Matsueda S, Fujii T, Itoh K (2004) Identification of HER2/neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients. Breast Cancer Res Treat 86:19–29PubMedCrossRef
84.
Seliger B, Harders C, Lohmann S et al (1998) Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts. Eur J Immunol 28:122–133PubMedCrossRef
85.
Schrier PI, Versteeg R, Peltenburg LT, Plomp AC, van‘t Veer LJ LJ, Krüse-Wolters KM (1991) Sensitivity of melanoma cell lines to natural killer cells: a role for oncogene-modulated HLA class I expression? Semin Cancer Biol 2:73–83PubMed
86.
Choudhury A, Charo J, Parapuram SK et al (2004) Small interfering RNA (siRNA) inhibits the expression of the Her2/neu gene, upregulates HLA class I and induces apoptosis of Her2/neu positive tumor cell lines. Int J Cancer 108:71–77PubMedCrossRef
87.
Herrmann F, Lehr H, Drexler I et al (2004) HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 64:215–220PubMedCrossRef
88.
Vertuani S, Triulzi C, Roos AK et al (2009) HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice. Cancer Immunol Immunother 58:653–664PubMedCrossRef
89.
Limentani S, Dorval T, White S et al. (2005) Phase I dose-escalation trial of a recombinant HER2 vaccine in patients with stage II/III HER2+ breast cancer. ASCO Abstract 520
90.
Kitano S, Kageyama S, Nagata Y et al (2006) HER2-specific T-cell immune responses in patients vaccinated with truncated HER2 protein complexed with nanogels of cholesteryl pullulan. Clin Cancer Res 12:7397–7405PubMedCrossRef
91.
Kageyama S, Kitano S, Hirayama M et al (2008) Humoral immune responses in patients vaccinated with 1–146 HER2 protein complexed with cholesteryl pullulan nanogel. Cancer Sci 99:601–607PubMedCrossRef
92.
Baral R, Sherrat A, Das R, Foon KA, Bhattacharya-Chatterjee M (2001) Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human Her-2/neu. Int J Cancer 92:88–95PubMedCrossRef
93.
Mohanty K, Saha A, Pal S et al (2007) Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu. Breast Cancer Res Treat 104:1–11PubMedCrossRef
94.
Pal S, Saha A, Mohanty K et al (2007) Generation of Her-2/neu vaccine utilizing idiotypic network cascade. Cancer Biol Ther 6:1916–1925PubMedCrossRef
95.
96.
Coelho M, Gauthier P, Pugnière M, Roquet F, Pèlegrin A, Navarro-Teulon I (2004) Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice. Br J Cancer 90:2032–2041PubMedCrossRef
97.
Alvarez-Rueda N, Ladjemi MZ, Béhar G et al (2009) A llama single domain anti-idiotypic antibody mimicking HER2 as a vaccine: Immunogenicity and efficacy. Vaccine 27:4826–4833PubMedCrossRef
98.
Rescigno M, Avogadri F, Curigliano G (2007) Challenges and prospects of immunotherapy as cancer treatment. Biochim Biophys Acta 1776:108–123PubMed
99.
Mantovani A, Sica A, Sozzani S, Allavena P, Vecchi A, Locati M (2004) The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol 25:677–686PubMedCrossRef
100.
Kalinski P, Nakamura Y, Watchmaker P, Giermasz A, Muthuswamy R, Mailliard RB (2006) Helper roles of NK and CD8+ T cells in the induction of tumor immunity: polarized dendritic cells as cancer vaccines. Immunol Res 36:137–146PubMedCrossRef
101.
Nowak AK, Lake RA, Robinson BWS (2006) Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv Drug Deliv Rev 58:975–990PubMedCrossRef
102.
Lake RA, Robinson BWS (2005) Immunotherapy and chemotherapy: a practical partnership. Nat Rev Cancer 5:397–405PubMedCrossRef
103.
Nowak AK, Lake RA, Marzo AL et al (2003) Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170:4905–4913PubMed
104.
Rovere P, Vallinoto C, Bondanza A et al (1998) Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J Immunol 161:4467–4471PubMed
105.
Lutsiak MEC, Semnani RT, De Pascalis R, Kashmiri SVS, Schlom J, Sabzevari H (2005) Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105:2862–2868PubMedCrossRef
106.
Pegram M, Hsu S, Lewis G et al (1999) Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers. Oncogene 18:2241–2251PubMedCrossRef
107.
Emens LA, Asquith JM, Leatherman JM et al (2009) Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 27:5911–5918PubMedCrossRef
108.
Ellis MJ, Coop A, Singh B et al (2001) Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial. J Clin Oncol 19:3808–3816PubMed
109.
Reits EA, Hodge JW, Herberts CA et al (2006) Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 203:1259–1271PubMedCrossRef
110.
Zhang B, Li H, Guo L, Yan D, Liu J, Na Y (2007) Application of 64-slice helical CT in screening of coronary artery heart disease among apparently healthy people: preliminary experience. Zhonghua Yi Xue Za Zhi 87:556–558PubMed
111.
Nesslinger NJ, Sahota RA, Stone B et al (2007) Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res 13:1493–1502PubMedCrossRef
112.
Disis ML, Wallace DR, Gooley TA et al (2009) Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer. J Clin Oncol 27:4685–4692PubMedCrossRef
113.
Coveler AL, Goodell V, Webster DJ et al (2009) Common adjuvant breast cancer therapies do not inhibit cancer vaccine induced T cell immunity. Breast Cancer Res Treat 113:95–100PubMedCrossRef
114.
115.
Munn DH, Sharma MD, Hou D et al (2004) Expression of indoleamine 2, 3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J Clin Invest 114:280–290PubMed
116.
Friberg M, Jennings R, Alsarraj M et al (2002) Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection. Int J Cancer 101:151–155PubMedCrossRef
117.
Kaliński P, Vieira PL, Schuitemaker JH, de Jong EC, Kapsenberg ML (2001) Prostaglandin E(2) is a selective inducer of interleukin-12 p40 (IL-12p40) production and an inhibitor of bioactive IL-12p70 heterodimer. Blood 97:3466–3469PubMedCrossRef
118.
Johnson BF, Clay TM, Hobeika AC, Lyerly HK, Morse MA (2007) Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. Expert Opin Biol Ther 7:449–460PubMedCrossRef
119.
Pañares RL, Garcia AA (2007) Bevacizumab in the management of solid tumors. Expert Rev Anticancer Ther 7:433–445PubMedCrossRef
120.
Fakhrai H, Dorigo O, Shawler DL et al (1996) Eradication of established intracranial rat gliomas by transforming growth factor beta antisense gene therapy. Proc Natl Acad Sci USA 93:2909–2914PubMedCrossRef
121.
Smyth MJ, Takeda K, Hayakawa Y, Peschon JJ, van den Brink MRM, Yagita H (2003) Nature’s TRAIL-on a path to cancer immunotherapy. Immunity 18:1–6PubMedCrossRef
122.
Takeda K, Stagg J, Yagita H, Okumura K, Smyth MJ (2007) Targeting death-inducing receptors in cancer therapy. Oncogene 26:3745–3757PubMedCrossRef
123.
Stagg J, Sharkey J, Pommey S et al (2008) Antibodies targeted to TRAIL receptor-2 and ErbB-2 synergize in vivo and induce an antitumor immune response. Proc Natl Acad Sci USA 105:16254–16259PubMedCrossRef
124.
Hodi FS, Mihm MC, Soiffer RJ et al (2003) Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA 100:4712–4717PubMedCrossRef
125.
Hodi FS, Butler M, Oble DA et al (2008) Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 105:3005–3010PubMedCrossRef
126.
127.
Sica A, Bronte V (2007) Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest 117:1155–1166PubMedCrossRef
128.
Kiewe P, Thiel E (2008) Ertumaxomab: a trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs 17:1553–1558PubMedCrossRef
Metadata
Title
Anti-HER2 vaccines: new prospects for breast cancer therapy
Authors
Maha Zohra Ladjemi
William Jacot
Thierry Chardès
André Pèlegrin
Isabelle Navarro-Teulon
Publication date
01-09-2010
Publisher
Springer-Verlag
Published in
Cancer Immunology, Immunotherapy / Issue 9/2010
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-010-0869-2

Other articles of this Issue 9/2010

Cancer Immunology, Immunotherapy 9/2010 Go to the issue

Focussed Research Review

MHC-based detection of antigen-specific CD8+ T cell responses

Original Article

IL-12 enhances efficacy and shortens enrichment time in cytokine-induced killer cell immunotherapy

Original Article

Peptide microarrays for the profiling of cytotoxic T-lymphocyte activity using minimum numbers of cells

Original Article

Bioactivity and pharmacokinetics of two human serum albumin–thymosin α1-fusion proteins, rHSA-Tα1 and rHSA-L-Tα1, expressed in recombinant Pichia pastoris

Focussed Research Review

Modeling flow cytometry data for cancer vaccine immune monitoring

Meeting Report

CIMT 2009: report on the seventh annual meeting of the association for immunotherapy of cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits